Recombinant Pongo abelii Transmembrane protein 199 (TMEM199)

Advanced Research Questions

• How does TMEM199 contribute to V-ATPase assembly and function?

TMEM199 plays a critical role in V-ATPase complex assembly and function:

• Assembly Factor Role:

  • TMEM199 functions as a V-ATPase assembly factor, similar to its yeast homolog Vma12p/Vph2p

  • Genetic disruption of TMEM199 impairs V-ATPase assembly and function

• Endolysosomal Function:

  • TMEM199 is required for endolysosomal acidification

  • It facilitates lysosomal degradation processes

• Impact on Iron Metabolism:

  • V-ATPase disruption through TMEM199 knockout results in intracellular iron depletion

  • This iron depletion impairs prolyl hydroxylase domain (PHD) enzyme activity, leading to HIF1α stabilization

  • Iron supplementation can directly restore PHD catalytic activity following V-ATPase inhibition

• Lysosomal Quantity Regulation:

  • TMEM199 knockdown significantly decreases lysosome quantity

  • This affects protein degradation pathways, including those for PD-L1, EGFR, and HLA proteins

• What is known about TMEM199-congenital disorder of glycosylation (TMEM199-CDG)?

TMEM199-CDG is a rare autosomal recessive inherited disease with characteristic features:

• Clinical Presentation:

  • Chronically elevated serum transaminases (ALT: 23-437 IU/L; AST: 31-746 IU/L)

  • Decreased serum ceruloplasmin (0.03-0.24 g/L) and serum copper (2.80-8.60 μmol/L)

  • Elevated alkaline phosphatase (132-3990 IU/L)

  • Hypercholesterolemia (total: 5.3-9.3 mmol/L; LDL: 1.16-7.17 mmol/L)

  • Steatosis and/or fibrosis on liver biopsy

• Epidemiology:

  • Only eight patients reported worldwide (seven Europeans, one Chinese)

  • Age range: 2-41 years

  • Male predominance (six male, two female patients)

• Genetic Basis:

  • Mutations in the TMEM199 gene

  • Novel frameshift variant reported: c.128delA/p.Lys43Argfs*25

• Laboratory Diagnosis:

  • Reduced TMEM199 protein expression by immunohistochemistry

  • Abnormal protein glycosylation pattern consistent with type II CDG

  • Liver ultrastructure showing dilation and vesiculation of the Golgi and/or endoplasmic reticulum

• Treatment and Prognosis:

  • Limited treatment options with no definitive effect: bicyclic alcohol, zinc sulfate, penicillamine

  • Variable disease progression; some patients show no deterioration over decades

  • Cirrhosis detected in a Chinese patient suggests potentially unfavorable outcomes in some cases

• How does nuclear TMEM199 regulate immune response in cancer?

Recent research has revealed TMEM199 has important nuclear functions in immune regulation:

• Nuclear Localization and Function:

  • TMEM199 is detected in the nucleus of multiple cancer cell lines

  • It functions as a transcriptional co-factor regulating immune checkpoint genes

• PD-L1 Regulation Mechanism:

  • Nuclear TMEM199 binds to gene promoter sites of multiple factors that regulate PD-L1:

    • IFNGR1

    • IRF1

    • MTMR9

    • KAT8

    • Trim28

  • This binding induces PD-L1 mRNA expression, promoting immune escape

• Impact on Tumor Microenvironment:

  • TMEM199 knockdown reduces tumor size in xenograft models

  • TMEM199-depleted tumors show increased CD8+ and CD11b+ immune cell infiltration

  • CD4+ cells are decreased in TMEM199 knockdown xenografts

• Gene Expression Changes:

  • RNA-seq analysis of TMEM199 knockdown cells reveals enrichment in immune response and tumor necrosis factor-mediated signaling pathway genes

• What methodological approaches are used to study TMEM199's role in HIF1α regulation?

Multiple methodologies have been employed to elucidate TMEM199's role in HIF1α regulation:

• Genetic Screening:

  • Unbiased genome-wide genetic screen in near-haploid human cells identified TMEM199 as a regulator of HIF1α

  • CRISPR-Cas9 targeting of TMEM199 followed by FACS sorting for reporter activation

• HIF1α Assessment:

  • Reporter systems using GFP to measure HIF1α stabilization

  • Immunoblotting to confirm endogenous HIF1α accumulation in TMEM199-depleted cells

• Validation Approaches:

  • Rescue experiments with CRISPR-resistant TMEM199 expression

  • Generation of TMEM199 knockout clones to confirm HIF1α accumulation

  • Reconstitution experiments in clonal cells to reverse HIF1α accumulation

• Mechanistic Studies:

  • Iron supplementation experiments to determine the link between V-ATPase, iron metabolism, and HIF1α regulation

  • Analysis of prolyl hydroxylase (PHD) activity following V-ATPase inhibition

• What are the emerging therapeutic approaches targeting TMEM199?

Research suggests potential therapeutic applications related to TMEM199:

• Proton Pump Inhibitor Effects:

  • The proton pump inhibitor (PPI) omeprazole significantly decreases TMEM199 protein levels

  • Correspondingly, CD274 (PD-L1) mRNA is largely decreased by omeprazole treatment

• Implications for Immunotherapy:

  • TMEM199 is identified as a targetable immune regulator

  • PPI application disrupts immune therapy in clinical settings

  • Research is ongoing to elucidate TMEM199's role in influencing PPI immunotherapy efficacy

• Potential Therapeutic Targets:

  • Nuclear TMEM199 function as a transcriptional regulator offers novel targeting opportunities

  • Modulation of TMEM199 expression could potentially enhance immune cell infiltration in tumors

  • Alternative approaches to target downstream effectors in TMEM199-regulated pathways

• Considerations for TMEM199-CDG:

  • No definitive treatments exist for TMEM199-CDG

  • Current approaches (vitamin D, penicillamine, bicyclic alcohol, zinc sulfate) show limited effectiveness

  • Development of targeted therapies for this rare disorder remains an unmet need

• How do experimental conditions affect recombinant TMEM199 expression and purification?

Optimizing experimental conditions is critical for successful work with recombinant TMEM199:

• Expression Systems:

  • E. coli remains the primary expression system for recombinant Pongo abelii TMEM199

  • Expression construct design typically includes N-terminal His-tagging for purification

• Purification Strategies:

  • Denaturing conditions may be necessary for initial purification:

    • Denaturing lysis buffer (50 mM Tris-HCl pH 8, 500 mM NaCl, 8 M urea, 20 mM imidazole)

    • Gradual removal of urea during column washing to promote proper refolding

  • Nickel-nitrilotriacetic acid-agarose affinity chromatography is the standard purification method

• Protein Stability Considerations:

  • Addition of cryoprotectants (glycerol, trehalose) is essential for maintaining protein stability

  • Protein concentration is typically maintained at 0.1-1.0 mg/mL

  • pH optimization around 8.0 appears optimal for recombinant TMEM199

• Quality Control Measures:

  • SDS-PAGE for purity assessment (>90% standard)

  • Mass spectrometry for sequence verification

  • Functional assays to confirm biological activity

• What analytical techniques are used to study TMEM199 interactions with binding partners?

Multiple advanced analytical techniques are employed to characterize TMEM199 protein-protein interactions:

• Co-Immunoprecipitation with Mass Spectrometry (Co-IP/MS):

  • TMEM199 interacting proteins (TIPs) are pulled down using anti-TMEM199 antibodies

  • Mass spectrometry identifies binding partners

  • Gene Ontology-Cellular Component (GOCC) analysis reveals functional localization patterns

• Cut&Tag Assay:

  • Used to globally analyze TMEM199-bound gene sites

  • Identified binding to promoters of IFNGR1, IRF1, MTMR9, KAT8, and Trim28

• Direct Interaction Studies:

  • Examination of potential direct interactions with proteins like PD-L1

  • Western blot analysis following immunoprecipitation

• Peptide Binding Assays:

  • Synthetic peptide fragments for mapping interaction domains

  • HPLC and MALDI-TOF-MS for characterization

  • Acetylation and amidation modifications to stabilize peptides for interaction studies